Blanket Purchase Agreement 36F79721D0260-36E79722A0001
Award Date
10/7/21
Last Date to Order
10/6/26
Federal Agency
National Acquisition Center
Awardee
Astellas Pharma US, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the Department of Veterans Affairs' National Acquisition Center to Bayer Healthcare Pharmaceuticals Inc., a subsidiary of the global pharmaceutical company Bayer AG. The $6,788,810.45 single-award BPA is for the procurement of Xofigo (radium Ra 223 dichloride) and Adempas (riociguat), specialized pharmaceutical products used to treat prostate cancer and pulmonary arterial hypertension,...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the U.S. federal government, to Takeda Pharmaceuticals America Inc., a foreign-owned, for-profit manufacturer of specialized pharmaceutical products. The BPA, valued at $131,039,520.00, is a single-award contract that falls under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule. It enables the procurement of various critical medications such as CINRYZE,...
This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian federal agency, to Merz Pharmaceuticals, LLC, a for-profit foreign-owned organization. The BPA is established under the GSA Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs, with a ceiling value of $12,057,300.00 and a period of performance running through March 12, 2026. The purpose of this BPA is to provide the agency with the pharmaceutical products Ampyra and Inbrijia. No...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The BPA has a ceiling value of $118,500,000 and a period of performance from August 2024 to August 2026, with an option year extending it to August 2027. The BPA is for the procurement of specialized pharmaceutical products, primarily focused on medications for the treatment of rare diseases and pulmonary...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Acer Therapeutics Inc. The contract has a ceiling value of $1,891,583.25 and a period of performance through July 7, 2026. The BPA is for the procurement of MIPLYFFA and OLPRUVA, two pharmaceutical products. No set-asides were used, and this was a single-award contract. The contract vehicle is based on the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) managed by the...
The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Genzyme Corporation, doing business as Sanofi Genzyme. The BPA has a ceiling value of $3,000,000 and a period of performance from June 6, 2024 to June 5, 2026. The purpose of the BPA is to provide the VA with a streamlined contracting method to procure specialty pharmaceutical products,...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Advanced Accelerator Applications USA Inc., a large, foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products. The $23.4 million single-award BPA is under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of February 3, 2025. The BPA is for the procurement of LOCAMETZ and NETSPOT, two...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Mayne Pharma Commercial LLC, doing business as Metrics Inc. The BPA is for the procurement of halobetasol and tazaroten pharmaceuticals under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The single-award BPA has a ceiling value of $5,216,518.00 and a period of performance through May 28, 2025. As a foreign-owned, for-profit manufacturer of goods, Mayne...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Civica Inc., a non-profit organization and manufacturer of goods. The BPA has a ceiling value of $625,000.00 and a period of performance ending on April 3, 2026. The BPA is for the procurement of the pharmaceutical products daptomycin, lorazepam, phenylephrine, and anectine. As a BPA, this contract vehicle allows the agency to place individual task orders for these products as needed...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to HRA Pharma America, Inc. as the prime contractor. The BPA has a period of performance from June 10, 2025 to June 9, 2026 and a ceiling value of $1,386,062.00. The BPA is for the procurement of the pharmaceutical products Lysodren and Metopirone. No set-asides were used for this single-award contract. The purpose of this BPA is to establish a contract vehicle through which the...